Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market has been growing steadily in Kenya over the past few years, driven by a combination of factors such as rising prevalence of rheumatoid arthritis in the country, increasing awareness about the disease, and growing availability of effective treatment options.
Customer preferences: Patients suffering from rheumatoid arthritis in Kenya are increasingly preferring biologic drugs over traditional disease-modifying anti-rheumatic drugs (DMARDs) due to their higher efficacy and lower side effects. Additionally, there is a growing demand for self-administered biologic drugs, as they offer greater convenience and flexibility to patients.
Trends in the market: The Anti-Rheumatic Drugs market in Kenya has been witnessing a shift towards biologic drugs, which are expected to dominate the market in the coming years. The market is also witnessing the entry of new players, who are introducing innovative drugs that offer better efficacy and safety profiles. Furthermore, there is a growing trend towards personalized medicine, with drugs being tailored to individual patient needs based on their genetic makeup.
Local special circumstances: The healthcare system in Kenya is characterized by a shortage of healthcare professionals, inadequate infrastructure, and limited access to healthcare services in rural areas. This has resulted in a lack of awareness about rheumatoid arthritis and its treatment options among patients and healthcare providers. However, the government has taken steps to address these issues by increasing healthcare spending, expanding healthcare infrastructure, and promoting awareness about rheumatoid arthritis through public health campaigns.
Underlying macroeconomic factors: Kenya's economy has been growing at a steady pace over the past few years, driven by strong performance in the services and agricultural sectors. This has led to an increase in disposable incomes and healthcare spending, which has in turn boosted demand for Anti-Rheumatic Drugs. Additionally, the government's commitment to universal healthcare coverage is expected to further drive growth in the Anti-Rheumatic Drugs market by increasing access to healthcare services and medicines.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
